Risk factor
Very vulnerable to price shocks
Profitability factor
Overvalued vs peers
About
Globally, Cochlear Limited specializes in the development and provision of implantable auditory solutions for both children and adults. The company's diverse offerings include advanced cochlear implant systems, upgrades for sound processors, bone conduction devices, and a wide array of accessories and other related items. Established in 1981, its global operations are directed from its headquarters in Sydney, Australia.
Company Valuation
From both historical and forecast perspectives, the stock is overpriced compared to similar stocks. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITD
Target Price
The average target price of COH.AX is 138 and suggests 0.874% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to